Summary by Moomoo AI
On January 12, 2024, In8bio, Inc., a Delaware-based clinical-stage biopharmaceutical company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC). The filing pertains to the proposed sale of up to 42,703,475 shares of common stock by selling stockholders. These shares include those issued in a private placement on December 13, 2023, and shares pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares nor receive proceeds from the selling stockholders' sales, but will receive proceeds from any cash exercises of warrants. The shares may be sold from time to time after the registration statement becomes effective, at market prices or negotiated prices through various methods including block trades and underwriters. The company's common stock is listed on the Nasdaq Global Market under the symbol 'INAB'.